Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors
Open Access
- 19 January 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 44 (3) , 132-139
Abstract
There have been unique adverse events reported with targeted blockade of programmed death-1 (PD-1), programmed death-ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated protein-4 (CTLA4), including immune mediated toxicities. Recently, there have been reports of hepatitis B reactivation (HBVr) occurring with PD-1/PD-L1 inhibitors, which may result in treatment delays, interruptions, or discontinuation. This retrospective literature review and analysis of the Food and Drug Administration’s (FDA) Adverse Events Reporting System (FAERS) queried reported cases of “Hepatitis B reactivation” reported with the PD-1/PD-L1 inhibitors “Pembrolizumab,” “Atezolizumab,” “Nivolumab,” “Durvalumab,” “Avelumab,” and “Ipilimumab” from initial FDA approval to June 30, 2020. Disproportionality signal analysis was determined by calculating a reporting odds ratio (ROR) and 95% confidence intervals (CI). The ROR was considered significant when the lower and upper limits of the 95% CI were >1 and confirmed by the Fisher exact test (PP=0.013) and was the only statistically significant finding. There were no reports of HBVr with Ipilimumab or Avelumab. Additional prospective studies should be conducted to validate the findings of this retrospective pharmacovigilance analysis to determine the risk of HBVr in patients receiving immune checkpoint inhibitors.Keywords
This publication has 47 references indexed in Scilit:
- A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical applicationNature Immunology, 2013
- Management of Immune-Related Adverse Events and Kinetics of Response With IpilimumabJournal of Clinical Oncology, 2012
- PD-1 Blockage Reverses Immune Dysfunction and Hepatitis B Viral Persistence in a Mouse Animal ModelPLOS ONE, 2012
- Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicityVaccine, 2012
- Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of originHepatology, 2011
- Unmasking tuberculosis in the era of antiretroviral treatmentEuropean Respiratory Journal, 2011
- Chronic hepatitis B: Update 2009 #Hepatology, 2009
- Reprogramming of antiviral T cells prevents inactivation and restores T cell activity during persistent viral infectionJournal of Clinical Investigation, 2006
- Immune Reconstitution Hepatitis in HIV and Hepatitis B Coinfection, Despite Lamivudine Therapy as Part of HAARTClinical Infectious Diseases, 2004
- PD-1 Inhibits Antiviral Immunity at the Effector Phase in the LiverJournal of Experimental Medicine, 2003